ArticleCancer research and treatment2016

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer.

Guiyun Sohn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.